Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$21.9M+23.6%-$13.47M+25.6%-$14.21M-45.9%-$16.87M-16.6%-$28.66M-130%
$585K+93.1%$538K+132%$385K+15.6%$347K+16.1%$303K+5.6%
$5.41M+92.8%$4.3M+177%$4.48M+127%$4.8M+220%$2.8M+107%
-$23.83M-19.3%-$8.63M+39.6%-$8.73M+9.2%-$13.59M-11.1%-$19.98M-64.5%
$1.38M+314%$1.9M+239%$1.28M-33.3%$1.78M+251%$333K-18.0%
$21.84M+112%-$179.12M-2,443%
$623K-99.7%$1.06M-98.1%$2.65M+326%$42K+139%$211.12M+3,518,550%
-$1.37M-111%$3.41M-23.4%$12.02M+368%
-$25.21M-24.1%-$10.53M+29.0%-$10.01M+13.2%-$15.37M-20.6%-$20.31M-61.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Beta Bionics, Inc. Common Stock generate?
Beta Bionics, Inc. Common Stock (BBNX) generated -$54.8M in operating cash flow over the trailing twelve months.
What is Beta Bionics, Inc. Common Stock's free cash flow?
After $6.3M of capital expenditures, Beta Bionics, Inc. Common Stock's free cash flow was -$61.1M over the trailing twelve months, down 2.9% year over year.
Where does Beta Bionics, Inc. Common Stock's cash flow data come from?
Every line is extracted from Beta Bionics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.